This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

WCLC, Barcelona, Spain 7-10 September 2019

Afatinib in EGFR mutation-positive NSCLC harbouring uncommon mutations: experience in ‘real-world’ clinical practice

Wolfgang Brückl, Eckart Laack, Christopher Hoffmann, Caicun Zhou, Yi-Long Wu

wclc_2019_uncommon_mutations_.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

UNCOMMON EGFR MUTATIONS

Go to Page

UNCOMMON EGFR MUTATIONS

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

WCLC 2019

Find information on Boehringer Ingelheim’s activities at WCLC 2019
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY.

image